Tofacitinib, a prevalent JAK1 and JAK3 inhibitor, has been successfully tested in preclinical studies and afterwards in phase I/II clinical trials with good results in the improvement of cardiometabolic and immunologic parameters associated with the premature atherosclerosis in SLE, including type I IFN gene signature and circulating NETs [252]. The gene discussed is JAK1; the disease is systemic lupus erythematosus.